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Purpose: To investigate the differences in the histopathology and matrix metalloproteinase (MMP) 
expression in the Tenon’s tissue of primary open‐angle glaucoma (POAG) patients, primary angle‐closure 
glaucoma (PACG) patients, and non‐glaucomatous patients.
Methods: POAG and PACG patients, who underwent a trabeculectomy and had no history of ocular disease 
except glaucoma, were enrolled. The number and instillation period of topical eye drops were reviewed. For 
the controls, which were patients without glaucoma or a history of ocular surgery, the Tenon’s tissue was 
obtained in the course of retinal detachment surgery. For glaucoma patients, the Tenon’s tissue was 
obtained during the trabeculectomy. H&E and Masson’s trichrome staining and immunohistochemistry for 
MMP-1, MMP-2, and MMP-9 were performed. A total of six eyes of POAG, six eyes of PACG, and four 
control eyes were evaluated.
Results: The duration of topical anti-glaucoma medication and the mean number of anti-glaucoma 
medications were similar in the POAG and PACG groups. The levels of MMP-1 and 2 were elevated in the 
POAG and PACG groups compared to the control group (p=0.03, 0.01, respectively). Compared with the 
control group, the MMP-2 level was higher in the POAG patients (p=0.01), whereas the MMP-1 was higher 
in the PACG patients (p=0.04). The levels of MMP-9 in the POAG and PACG patients were not significantly 
different from that of the control patients (p=0.48, 0.26). The levels of MMP-2 were significantly lower in the 
PACG patients than in the POAG patients (p=0.02).
Conclusions: The MMP expression was altered in the Tenon’s tissue of glaucoma patients compared to the 
control group. The levels of MMP-2 were lower in the PACG patients than in the POAG patients. These 
results suggest that there may be histopathological differences in the Tenon’s tissue of POAG and PACG 
patients.
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Scarring of the filtering bleb is the most common cause 
of failure in glaucoma filtering surgery.
1,2 Wound healing is 
a complex process involving several phases, and the bleb 
failure in filtering surgery involves the proliferation of 
fibroblasts. Fibroblast proliferation, with the secretion of 
excessive extracellular matrix (ECM), is believed to play a 
key role in wound healing.
3 Matrix metalloproteinases 
(MMPs)
4 are a family of enzymes that are involved in tissue 
remodeling under various physiological and pathological 
conditions. Thus, the evaluation of MMP expression in 
glaucoma patients has implications on scarring of the filtering 
bleb. Moreover, the different mechanisms of primary 
open-angle glaucoma (POAG) and primary angle-closure 
glaucoma (PACG) might play a role in the variable 
expression of MMPs compared with normal controls.
5 In a 
previous study, there were differences in the expression levels Kor  J  Ophthalmol  Vol.22,  No.1,  2008
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Grade Description
0 The  same  as  the  control  eye
1 1%-25%  of  control
2 26%-50%  of  control
3 51%-75%  of  control
4 >75%  of  control
S c a l e  - 4  t o  + 4 ;  0  i s  t h e  s a m e  a s  t h e  c o n t r o l ;  P r e f i x  +  : in d i c a ting 
more  than  control;  Prefix  -  :  indicating  less  than  control.
Table  1.  MMP  grading  described  by  Shah  et  al.
6
of MMPs between POAG and PACG as shown by the 
reverse transcriptase-polymerase chain reaction (RT-PCR) 
method.
5 However, this study was not confirmed by 
histopathologic evaluation. The present study investigated 
the differences in the histopathology and matrix 
metalloproteinase expression in the Tenon’s tissue of POAG 
and PACG patients and non-glaucomatous patients, who 
served as controls.
Materials and Methods
Patients with POAG or PACG who underwent a 
trabeculectomy by a single surgeon (K.H.P.) from May 2005 
to January 2006 at Seoul National University Hospital were 
enrolled in this study. Patients with simple rhegmatogenous 
retinal detachment without any other ocular or systemic 
diseases were used as controls. The Tenon’s tissue, which 
was obtained in the course of the trabeculectomy or surgery 
for retinal detachment, was obtained from an area 2-3 mm 
posterior to the limbus at the beginning of the operation. A 
sample of Tenon’s tissue approximately 2×2 mm in size was 
excised in each case. A diagnosis of glaucoma was made 
based on an optic disc examination and the presence of a 
visual field defect. POAG was defined according to the 
following criteria: highest intraocular pressure (IOP) of 21 
mmHg or higher without any medication, glaucomatous optic 
neuropathy, a glaucomatous visual field defect, an open 
iridocorneal angle, and no neuroradiological evidence of a 
non‐glaucomatous cause for the optic nerve damage. PACG 
was diagnosed according to the following criteria: the 
gonioscopic verification of angle closure with an elevated 
IOP, the presence of peripheral anterior synechiae, and/or 
appositional angle closure either with acute or chronic 
symptoms, characteristic glaucomatous optic nerve head 
damage, and glaucomatous visual field loss. Patients with a 
prior history of ocular surgery, systemic diseases, or other 
ocular diseases were excluded. Informed consent was 
obtained from all subjects, and all performed procedures were 
consistent with the tenets of the Helsinki Declaration. The 
patients’ medical records were reviewed for age, number, and 
instillation course of topical eye drops, and the preoperative 
and postoperative IOP. Six eyes from six POAG patients, six 
eyes from six PACG patients, and four eyes from four 
controls were examined.
Experimental procedures
The tissue samples from 16 patients were fixed in neutral 
buffered 10% formalin for 24 hours. The tissues were then 
embedded in paraffin wax. Four micron sections were cut and 
stained by routine methods with hematoxylin and eosin 
(H&E) for the histopathological examination and with 
Masson’s trichrome for an evaluation of the fibrosis. Sections 
from the six POAG, six PACG, and four controls were 
examined with three antibodies according to a biotin- 
streptavidine peroxidase complex procedure (Dakocytomation, 
Carpinteria, CA, USA). The monoclonal antibodies used were 
anti-human MMP-1, 2, and 9 (1 in 100; Calbiochem, 
Cambridge, MA, USA). The dewaxed sections were subjected 
to antigen retrieval using 20 μg/ml proteinase kinases in 10 
minute courses, and endogenous peroxidase activity was 
blocked by exposing the sections to 3% H2O2 for 10 minutes. 
The sections were incubated with the primary antibody at 
room temperature for 3 hours, followed by incubation with 
the biotinylated secondary antibody for 30 minutes at room 
temperature. The sections were then incubated with 
streptavidin conjugate for 30 minutes. Three phosphate‐
buffered saline (PBS) washes were performed between each 
incubation. After three further washes, the sections were 
incubated with a diaminobenzidine solution (DAB substrate, 
Zymed laboratory Inc., San Francisco, CA, USA), 
counterstained with hematoxylin for 30 seconds, and then 
mounted with Balssam oil. Three of the sections were 
prepared with PBS instead of specific antibody (ie, antibody 
MMP-1, 2, and 9) and used as negative controls. Specimens 
of a colon adenocarcinoma, which is known to express 
MMPs, were harvested from a patient with a colon 
adenocarcinoma and used as the as the positive controls.
5 The 
cells expressing the MMPs acquired a brown‐chestnut 
coloration in the cytoplasm, enabling their identification and 
quantification.
Histometric and statistical analyses
Two independent, masked observers measured the MMP 
expression in the subjects, using the grading scheme 
proposed by Shah et al.
6 (Table 1). This grading was 
determined by comparison with the expression in the 
controls. The data was processed using SPSS v.12.0 software 
(SPSS Inc., Chicago, IL). A Mann‐Whitney U test was 
used, and a two‐sided  p-value of < 0.05 was considered 
significant.
Results
The mean age of the POAG and PACG patients at the 
time of surgery was 59.0±14.6 years and 68.3±4.5 years, 
respectively (p=0.31). The preoperative IOP in the POAG 
and PACG patients was 22.2±4.4 mmHg and 27.5±17.3 
mmHg, respectively (p=0.48) The mean age of the control JH  Seo,  et  al.  MMP  IN  TENON’S  TISSUE  POAG  AND  PACG
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POAG PACG p-value Control
Age  (year),  range 59.0±14.6,  35-65 68.3±4.5,  50-73 0.31  53.0±13.1,  37-66
Preop  mean  IOP  (mm  Hg),  22.2±4.4 27.5±17.3 0.48 13.5±1.3
Medication  duration  (months) 38.6±17.4 59.3±35.1 0.22 0.0
Preoperative  glaucoma  medication
    Mean  number 3.3±0.8 3.3±1.3 0.93 0.0
Drug:  Number  of  patients  (%)
  P i l o c a r p i n e 0  (0) 2  (33.3) 0.14 0.0
    Beta  blocker
†     6  (100) 6  (100) 1.0 0.0
  D o r z o l a m i d e     4  (66.6) 4  (66.6) 1.0 0.0
  A l p h a  a g o n i s t
‡     4  (66.6) 2  (33.3) 0.29 0.0
    PG  analogue
§   6  (100) 6  (100) 1.0 0.0
POAG=Primary  open-angle  glaucoma;  PACG=Primary  angle-closure  glaucoma; 
* D a t a  a r e  g i v e n  a s  m e a n ±s t a n d a r d  d e v i a t i o n  o f  
variables  or  numbers  (percent); 
†T i m o p t i c  X E  w e r e  u s e d ;  
‡Alphagan,  Iopidine  were  used; 
§  Xalatan,  Lumigan  were  used.
Table  2.  Preoperative  clinical  data  of  the  glaucoma  patients  and  control  patients
patients at the time of surgery was 53.0±13.1 and their mean 
preoperative IOP was 13.5±1.3 mmHg (Table 2). The 
Tenon’s tissues of both the POAG and the PACG patients 
showed significant increases in the subepithelial collagen and 
fibroblast density under H&E and Masson’s trichrome 
staining. The fibrosis appeared to be more advanced in the 
POAG patients than in the PACG patients under H&E and 
Masson’s trichrome staining (Fig. 1). The levels of MMP-1 
and 2 were elevated in the POAG and PACG groups 
compared to the control group (p=0.03 and 0.01, respectively, 
Table 3). However, the level of MMP-9 was not significantly 
different between the glaucoma groups and control group 
(p=0.86). Comparing the POAG group and the control group, 
the level of MMP-2 was higher in the POAG patients 
(p=0.01), while the levels of MMP-1 and 9 were not different 
(p=0.11, and 0.48, respectively). Also, comparing the PACG 
group and control group, the level of MMP-1 was higher in 
the PACG group (p=0.04), while the levels of MMP-2 and 
9 in the PACG group and the control group were not 
significantly different (p=0.11, and 0.26). Furthermore, 
comparing POAG and PACG, the level of MMP-2 was 
significantly lower in the PACG patients than in the POAG 
patients (p=0.02); however, the levels of MMP-1 and 9 were 
not significantly different between them (p=0.40, and 0.24).
Discussion
In this study, the MMP-1 and 2 expressions were increased 
in the Tenon’s tissue samples of glaucoma groups compared 
to the control group, and the level of MMP-2 was lower in 
the PACG group than in the POAG group. MMPs are 
generally divided into four categories
7: the collagenases, 
which recognize native fibrillar collagen types 1, 2, and 3; 
gelatinases, which degrade denatured collagens; stromelysin, 
which recognizes a variety of collagens; and membrane-type 
(MT)-MMPs, which are cell-surface bound and are involved 
in a variety of pericellular activities. MMPs are the major 
degrading enzymes of the extracellular matrix (ECM); they 
are involved in cell signaling, neovascularization, and 
activation of other proteinases.
8 MMP-1 acts as a collagenase, 
whereas MMP-2 and 9 act as gelatinases. A previous study
9 
on corneal wound healing after the keratectomy showed the 
up-regulation of MMP-2 and 9. Liu et al.
5 reported that the 
PACG patients had lower levels of MMP-2 mRNA in the 
Tenon’s capsule than the POAG patients. These results agree 
with the results of our study, which suggest that the MMP-2 
level was higher in POAG group than in the PACG group. 
Although, in the present study, the PACG patients had a 
similar IOP to that of the POAG patients, the IOP of the 
PACG patients was 10 mmHg higher than that of the POAG 
patients in Liu et al.’s study.
However, in another study,
5 the PACG and POAG groups 
had lower MMP-2 mRNA levels in Tenon’s capsule than the 
control group. These results were in contrast to our study 
results, which suggest that MMP-2 was expressed more 
strongly in the POAG and PACG groups than in the control 
group. Bradley et al.
10 reported that trabecular cells might 
sense increases in the IOP and respond by increasing the 
MMP-2 and MMP-14 levels. This report provided the 
following clue that can explain the results of the present 
study: preoperative, elevated IOP can increase the expression 
of MMPs in both POAG and PACG patients.
MMP-9, which is known as gelatinase B, is a likely 
candidate for mediating the proteolysis based on its selective 
presence in leaking bleb tissue. Chintala et al.
11 reported that 
MMP-9 is associated with leaking glaucoma filtering blebs 
and might be directly involved in the degradation of the 
conjunctival tissue associated with bleb failure. In this study, 
the levels of MMP-9 in the POAG and PACG patients were 
similar to those of the controls. This suggests that the leakage 
of a filtering bleb is not dependent on the preoperative or 
intraoperative conditions, but rather on the postoperative changes.Kor  J  Ophthalmol  Vol.22,  No.1,  2008
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Fig.  1. H & E  s t a i n ,  M a s s o n ’s  Trichrome  stain,  and  immunohistochemistry  of  the  Tenon’s  tissue  of  the  control  group  (A),  POAG  group 
(B),  PACG  group  (C),  Positive  Control  (D:  adenocarcinoma  of  colon),  Negative  Control  (E:  sections  were  prepared  with  PBS  instead  of 
primary  antibody  MMP-1,  2,  and  9)  (magnification  ×200)
The Tenon’s tissue of both the POAG and the PACG patients under H&E and M asson’s trichrome staining showed higher subepithelial 
collagen  and fibroblast  density than  that  of  the  controls. The fibrosis under  H&E and  Masson’s  trichrome staining  appeared  to  be  more 
advanced in the POAG patients than in the PACG patients (arrow). Compared with the controls, the level of MMP-1 and 2 were higher 
in  the  POAG  patients  (grade  2,  3,  respectively).  The  expression o f  M M P - 2  w a s  l o w e r  i n  t h e  P A C G  p a t i e n t s  t h a n  t h e  P O A G  p a t i e n t s . 
The  level  of  MMP-9  was  less  in  POAG  and  PACG  patients  than  the  controls.
The POAG patients showed more fibrosis in the Tenon’s 
tissue than the PACG patients (Fig. 1). This result agrees 
with previous studies.
12-14 A histopathological image of the 
bulbar conjunctiva of the PACG and POAG patients 
receiving topical anti-glaucoma medication revealed 
inflammation, fibrosis, and the proliferation of fibroblasts.
12 
The long‐term use of topical glaucoma therapy induces 
subclinical inflammation, and the repeated use of topical 
medication might induce conjunctival changes, such as 
squamous metaplasia, inflammation, and subconjuntival 
fibrosis.
13 Depending on the type of medication, a significant 
increase in the subepithelial collagen density, degeneration of 
fibrocytes, and decrease in the ECM can occur. Neuciu et 
al.
13 have suggested that these results correlate with 
benazalkonium chloride. This inflammatory condition activates 
the MMPs and degrades the ECM. Nuzzi et al.
14 
demonstrated that the subconjunctival connective tissue of 
glaucoma patients is more compact and richer in collagen 
fibers than that of the controls. This may be due to an effect 
of the medication on the subconjunctival tissue. Animal 
studies also have shown increased subepithelial fibrosis of the 
subconjunctiva in the eyes treated with topical glaucoma 
medication.
15
In this study, even though the PACG patients underwent 
a similar course of topical glaucoma medication to that of the 
POAG patients, the POAG patients showed higher levels of 
fibrosis and MMP expression than the PACG patients. This 
suggests that factors other than the glaucoma medication are 
responsible for this discrepancy. The open-angle means that 
the anterior chamber angle structures are visible by JH  Seo,  et  al.  MMP  IN  TENON’S  TISSUE  POAG  AND  PACG
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MMP-1 MMP-2 MMP-9
POAG
  P O A G 1 2 4 - 1
    P O A G 2 443
    P O A G 3 - 13- 1
    P O A G 4 231
  P O A G 5 3 4 - 1
  P O A G 6 4 3 - 1
Average  of  POAG’s2 . 3 3 ±1.86 3.50±0.54 0.00±1.67
PACG
    P A C G 1 221
    P A C G 2 222
    P A C G 3 200
  P A C G 4 3 0 - 1
    P A C G 5 232
    P A C G 6 032
Average  of  PACG’s1 . 8 3 ±0.98 1.66±1.37 1.00±1.26
C o n t r o l 000
Comparisons  of  groups
* p-value  in  MMP-1 p-value  in  MMP-2 p-value  in  MMP-9
  Glaucoma  vs.  Control 0.03
* 0.01
* 0.86
  P O A G  v s .  C o n t r o l 0 . 1 1 0.01
* 0.48
    PACG  vs.  Control 0.04
* 0.11 0.26
  POAG  vs.  PACG 0.40 0.02
* 0.24
* p-value,  Man-Whitney  U t e s t  ( p<.05  is  significant);  For  Control  group  grade  as  Grade  0.
Table  3.  Summary  of  the  grading  of  patients
gonioscopy.
16 However, with an elevated IOP, there are many 
possible mechanisms
17; the elements obstructing the aqueous 
outflow may be located on either of the following: the 
anterior chamber side of the trabecular meshwork, within the 
trabeculum, or the post‐trabecular meshwork. In the 
post-trabecular mechanism, an obstruction of aqueous 
outflow can result from the increased resistance in the 
Schelmm’s canal due to the collapse or absence of the canal 
or an elevated episcleral venous pressure. On the other hand, 
the angle-closure mechanisms include those in which the 
peripheral iris is in apposition to the trabecular meshwork or 
the peripheral cornea. The peripheral iris can be pulled or 
pushed into this position. The differences in mechanisms 
between POAG and PACG might affect the differences in 
uses of anti-glaucoma medications, which may result in 
differential expression of the ECM and MMPs.
In conclusion, the Tenon’s tissue of the POAG and PACG 
patients showed increased fibrosis compared to the controls, 
and the Tenon’s tissue of the POAG patients showed a higher 
level of fibrosis and collagen than that of the PACG patients. 
The levels of MMP-2 in POAG patients were higher than 
those in the controls. The levels of MMP-2 were lower in 
the PACG patients than in the POAG patients. There might 
be some histopathological and molecular differences in the 
Tenon’s tissue between POAG and PACG patients. However, 
these results should be verified in a future study with a larger 
number of cases and a quantitative evaluation using the 
RT-PCR method proposed by Huang et al.
18
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